Comparison between Q-Line Biotec IPO and Vectras Enprocon IPO.
Q-Line Biotec IPO is a SME Bookbuilding IPO proposed to list at NSE SME while Vectras Enprocon IPO is a SME Bookbuilding proposed to list at BSE SME.
| Q-Line Biotec IPO | Vectras Enprocon IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Bookbuilding |
| Listing At | NSE SME | BSE SME |
| Lead Managers | Share India Capital Services Pvt.Ltd. Hem Securities Ltd. | Beeline Broking Ltd. |
| Registrar | Purva Sharegistry (India) Pvt.Ltd. | MUFG Intime India Pvt.Ltd. |
| Market Maker | Hem Finlease Pvt.Ltd. | |
| DRHP | DRHP  | DRHP |
| RHP | RHP | |
| Final Prospectus | Final Prospectus | |
| Anchor Investor | Anchor Investor | |
| IPO Allotment URL | IPO Allotment URL |
The total issue size of Q-Line Biotec IPO is up to ₹203.74 Cr whereas the issue size of the Vectras Enprocon IPO is up to ₹0.00 Cr. The final issue price of Q-Line Biotec IPO is ₹343.00 per share and of Vectras Enprocon IPO is .
| Q-Line Biotec IPO | Vectras Enprocon IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹326.00 per share | |
| Issue Price (Upper) | ₹343.00 per share | |
| Issue Price (Final) | ₹343.00 per share | |
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | 400 shares | |
| Fresh Issue Size | 59,40,000 shares | 50,00,000 shares |
| Fresh Issue Size (Amount) | up to ₹203.74 Cr | up to ₹0.00 Cr |
| OFS Issue Size | 0 shares | 10,00,000 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 59,40,000 shares | 60,00,000 shares |
| Issue Size Total (Amount) | up to ₹203.74 Cr | up to ₹0.00 Cr |
Q-Line Biotec IPO opens on May 21, 2026, while Vectras Enprocon IPO opens on . The closing date of Q-Line Biotec IPO and Vectras Enprocon IPO is May 25, 2026, and , respectively.
| Q-Line Biotec IPO | Vectras Enprocon IPO | |
|---|---|---|
| Anchor Bid Date | May 20, 2026 | |
| Issue Open | May 21, 2026 | |
| Issue Close | May 25, 2026 | |
| Basis Of Allotment (Tentative) | May 26, 2026 | |
| Initiation of Refunds (Tentative) | May 27, 2026 | |
| Credit of Share (Tentative) | May 27, 2026 | |
| Listing date (Tentative) | May 29, 2026 | |
| Anchor Lockin End date 1 | Jun 25, 2026 | |
| Anchor Lockin End date 2 | Aug 24, 2026 |
Q-Line Biotec IPO P/E ratio is 20.82, as compared to Vectras Enprocon IPO P/E ratio of .
| Q-Line Biotec IPO | Vectras Enprocon IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)
| Company Financials (Restated)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 96.77 | 100 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 20.82 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹800.16 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 23.74 | 59.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 17.66 | 55.94 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.87 | 0.53 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹16.47 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 23.74 | 59.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Q-Line Biotec IPO Retail Individual Investors (RII) are offered 20,79,200 shares while in Vectras Enprocon IPO retail investors are offered 20,79,200 shares. Qualified Institutional Buyers (QIB) are offered 11,88,000 shares in Q-Line Biotec IPO and 0 shares in Vectras Enprocon IPO.
| Q-Line Biotec IPO | Vectras Enprocon IPO | |
|---|---|---|
| Anchor Investor Reservation | 17,81,200 shares | 0 shares |
| Market Maker Reservation | 3,13,200 shares | 0 shares |
| QIB | 11,88,000 shares | 0 shares |
| NII | 8,91,600 shares | 0 shares |
| RII | 20,79,200 shares | 0 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 59,40,000 shares | 0 shares |
Q-Line Biotec IPO subscribed 71.71x in total, whereas Vectras Enprocon IPO subscribed .
| Q-Line Biotec IPO | Vectras Enprocon IPO | |
|---|---|---|
| QIB (times) | 123.94x | |
| NII (times) | 145.98x | |
| Big NII (times) | 178.29x | |
| Small NII (times) | 81.35x | |
| RII (times) | 71.44x | |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 71.71x |
